Repurposing the Hybrid Capture 2 (HC2) screening test for whole-genome sequencing of human papillomaviruses

A. Debernardi (1) , W. Jarassier (2) , C. Soret (2, 1) , C. Mougin (1, 2) , Samuel Alizon (3) , Ignacio G. Bravo (4) , D. Guenat (2, 1) , J. L. Prétet (2, 1) , Q. Lepiller (1, 2)

1 CEF2P / CARCINO - Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181)
2 CNRP - Centre National de Référence des Papillomavirus
3 CIRB - Centre interdisciplinaire de recherche en biologie
4 MIVEGEC-Virostyle - Virostyle

Simple and standardized approaches for genome analysis of human papillomavirus (HPV) by next-generation sequencing are needed. The aim of the study was to develop a protocol for direct deep sequencing of high-risk (hr) HPV strains, based on the widely used commercial Hybrid Capture 2 (QIAGEN) test, without any additional probe design. This protocol was applied to 15 HPV-positive and two HPV-negative cervical samples or cell lines and validated at the genotype level by comparing the sequencing results to those obtained using a commercial genotyping kit. The performance of our protocol, presented in this proof-of-principle study, supports its use for accurate characterization of genetic variants of hrHPV.

Domaines: Virologie; Génomique, Transcriptomique et Protéomique [q-bio.GN]

A. Debernardi, W. Jarassier, C. Soret, C. Mougin, Samuel Alizon, et al.. Repurposing the Hybrid Capture 2 (HC2) screening test for whole-genome sequencing of human papillomaviruses. Archives of Virology, 2021, 166 (12), pp.3421-3425. ⟨10.1007/s00705-021-05259-9⟩. ⟨hal-03425708⟩